Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Low-frequency deep brain stimulation improves difficult-to-treat Parkinson's symptoms

  • Fluorescent dyes 'light up' brain cancer cells

  • Some traumatic brain injury treatments are ineffective, research finds

  • Key discovery to preventing blindness, stroke devastation

  • Treating Cerebral Malaria: New Molecular Target Identified

  • Obesity, diabetes symptoms in mice improved by reversing brain inflammation

  • Outbreak of rare respiratory virus could be linked with paralysis in 12 Colorado children

  • Novel eye-tracking technology detects concussions, head injury severity

  • Beer compound could help fend off Alzheimer's and Parkinson's diseases

  • Why upper motor neurons degenerate in ALS

  •